This new agent, like the other DPP-4 inhibitors, has a mechanism of action that affects both pancreatic ß-cell survival as well as ß-cell secretory function. These medications do not incite ...

This is the first approved agent in a new class of antihyperglycemics, dipeptidyl peptidase (DPP)-4 inhibitors ... action, including T-cell activation and proliferation. Although the mechanism ...

Cinnamaldehyd demonstrates a broad pharmacological range ... Various methods were used to analyze the characteristics, mechanism of action, and targets of cinnamaldehyde (Liu et al., 2020). Firstly, ...

Objective Dipeptidyl peptidase-4 (DPP4), also known as CD26, is a transmembrane glycoprotein that has a costimulatory function in the immune response. DPP4 inhibitors (DPP4i ... These results may ...

SGLT-2 inhibitors, compared with DPP-4 inhibitors, were associated with a lower risk for liver cirrhosis among patients with type 2 diabetes. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors ...

In adults with type 2 diabetes and active COPD, the risk of moderate or severe COPD exacerbation was 14-19% lower with the two classes as compared with DPP-4 inhibitors, reported researchers led ...

Cell cycle re-entry of senescent breast cancer cells after CDK4/6 inhibition (CDK4/6i) constitutes a major source of disease ...

Immune checkpoint inhibitors (ICIs) have transformed cancer therapy by targeting key immune pathways such as PD-1, PD-L1, CTLA-4, and LAG-3 to enhance the immune system's ability to combat ...

Researchers obtained data from 601 randomized controlled trials enrolling adults with type 2 diabetes and assessing the efficacy of SGLT2 inhibitors, GLP-1s or DPP-IV inhibitors on HbA1c or major ...

Despite the established links between inflammation and cancer development, the effects of inflammatory signaling on cancer ...